Fresenius

15/02/2025

In the summer of 2024, Mika was diagnosed with acute lymphoblastic leukemia. In the video, Mika explains how his “strawberry filling station” works. 🍓⛽
Although he has a 90 percent chance of being cured, the treatment is an enormous burden for the boy and his family, both physically and mentally. That’s why the family also receives psychological support at the Helios Kliniken Schwerin.

To help him cope with this difficult time, Mika's father Jens Mehnert started a blog about Mika's journey (German only): www.mikasweg2024.de

We‘re sending him our best wishes for strength, health, and happiness on his journey ahead! We‘re sending him our best wishes for strength, health, and happiness on his journey ahead! 🎗️

04/02/2025

Every year, nearly 20 million people worldwide are diagnosed with cancer. This year’s World Cancer Day reminds us that every patient, every story, and every battle is unique.
 
At Fresenius, we are committed to holistic cancer care—supporting patients from diagnosis to treatment and beyond. Through innovative and accessible medicines, nutritional support, as well as personalized therapies and care, our ambition is to improve not just survival, but quality of life.
 
From Fresenius Kabi’s high-quality oncology treatments to Helios’ and Quirónsalud’s innovative and holistic patient care, our teams work tirelessly to make a difference.

Because behind every diagnosis is a person. 💙
 

30/01/2025

A real revolution in treatment of breast cancer! 🎗️

“Ninety percent of the women who were given an antibody–drug conjugate are still alive ten years later”, says Prof. Michael Untch, chief physician in the gynecology and obstetrics department and head of the certified centers for breast cancer and gynecological cancers at Helios Klinikum Berlin-Buch.

He and an international research team recently published the promising results of a global long-term study involving breast cancer patients who were treated with antibody-drug conjugates (ADCs). The new ADCs enable a much more targeted and therefore highly effective form of therapy to be administered – that is what is so special about it.

Learn more about ADCs in an interview with Prof. Untch: 👉 https://www.fresenius.com/adc-medicines

18/12/2024

Share your festive greetings using our holiday designs ☃️❄️
—> Because the holidays are a special time to say thank you, share joy and cultivate valuable relationships

05/12/2024

CAR-T cell therapy is one of the most innovative gene and cell therapies. The production process, however, is highly complex because each course of CAR-T cell therapy is individually tailored to each patient. 🧑‍🔬

The R&D Team Transfusion and Cell Therapies at Fresenius Kabi USA develops devices for the CAR-T cell therapy, trying to democratize the process and enabling broader patient access to these innovative treatments.

In a recent interview, Christopher Wegener, Director, Cell Therapy R&D, talks about the early days of device development for CAR-T cell therapy and how he sees the future of cell processing in the next five to ten years.🧫

Read the full interview here:

Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.

26/11/2024

The so-called CAR-T cell therapies are among the most innovative therapy options for malignant blood cancers, for example. They require the patient’s living cells, which are then prepared in a special way using an intricate process.🧫The entire production process for these cell-based therapeutics is extremely complex and logistically challenging, making therapeutic applications expensive and limiting their accessibility.

Fresenius Kabi is developing and producing two new devices that are essential to the CAR-T cell therapy process. Read more in our story about how the cell processing systems Lovo and Cue are revolutionizing the treatment of cancer patients by making the therapy production more efficient and accessible: 👉

How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.

17/11/2024

Dr. Eduard Fresenius laid the foundation for our global healthcare company by establishing a pharmaceutical enterprise in the back of his pharmacy. His entrepreneurial spirit still drives us today: For more than 100 years now, we have continued to evolve to help save and improve people’s lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
Today, on what would have been his 150th birthday, we remember his legacy that has led Fresenius to become a global leader in healthcare.

06/11/2024

NOW AVAILABLE: Our results for Q3/24.

Based on the first nine months of this year, we upgraded our Group outlook for fiscal 2024. Organic revenue growth is now expected to grow between 6% to 8% and EBIT growth in constant currency to be in the 8% to 11% range. 📈

Here are some of the key takeaways:
• Group organic revenue growth of 9% to €5.3 billion driven by a strong Kabi performance and good organic growth at Helios.
• Strong bottom-line traction: Group EBIT increase in constant currency of 9% to €552 million; EPS growth of 7%.
• Group-wide cost and productivity savings ahead of plan with target for FY/24 already achieved YTD.
• Excellent operating cash flow resulting from focused cash management.
• Progress on deleveraging: leverage ratio further improved to 3.24x driven by excellent cash flow; leverage target corridor under review.
• Fresenius Kabi delivering above the top-end of the structural growth band with organic revenue growth of 11%; strong EBIT margin at 15.9%.
• Continued strong performance of Growth Vectors at Kabi, led by dynamic growth at Biopharma; Tyenne is in line with expectations and building on strong momentum.
• Fresenius Helios with excellent organic revenue growth of 8%; EBIT margin of 7.9% in line with expectations due to anticipated lower seasonal demand in Spain; last quarter of energy relief funding support.
• Dedicated Helios performance program underway to drive further operational excellence and compensate ending energy relief funding in Germany.

Find our full press release here: https://www.fresenius.com/node/6945



Disclaimer: The caption is without corresponding footnotes, which can be retrieved from the slides.